Publications

June 6, 2026

Preclinical and Translational Assessment of Small Molecule IRF5 Inhibitors in Lupus-Relevant Systems

European Congress of Rheumatology 2026

Download

March 6, 2026

Preclinical Evaluation of IRF5 Small Molecule Inhibitors with Potent Activity in Lupus-Relevant Systems

15th European Lupus Meeting

Download

July 4, 2025

MSS/KRASG12XCRC Depends on CBM Signalosome for Survival -A Discovery that May Transform KRASG12XCRC Therapy

ESMO Gastrointestinal Cancers Congress 2025

Download

July 4, 2025

Synthetic Lethality of CBM Signalosome Inhibition for KRASG12X Colorectal Cancer

ESMO Gastrointestinal Cancers Congress 2025

Download

June 26, 2025

Targeting IRF5: Discovery and Preclinical Development of Selective Small Molecule Inhibitors

25th Annual Meeting of the Federation of Clinical Immunology Societies

Download

November 9, 2024

Peripheral Blood and Tumor Gene Expression as Biomarkers and Potential Predictors of Clinical Outcome with HST-1011, an Oral CBL-B Inhibitor

Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting

Download

October 23, 2024

Targeting the CBM Signalosome with a MALT1 Signalosome Glue for Treatment of NFκB Driven Solid Tumors

36th EORTC-NCI-AACR Symposium

Download

September 13, 2024

First-in-Human (FIH) Phase 1 Data of HST-1011, an Oral CBL-B Inhibitor, in Patients with Advanced Solid Tumors

European Society for Medical Oncology Congress 2024

Download

June 20, 2024

Targeting the CBM Signalosome with a MALT1 Scaffolding Inhibitor for Treatment of Non-Hodgkin Lymphomas

American Association for Cancer Research Annual Meeting 2024

Download

December 9, 2023

Discovery of the First MALT1 Allosteric Scaffolding Inhibitor

2023 American Society of Hematology Annual Meeting

Download

November 3, 2023

Exploring Proximal Biomarkers of CBL-B Inhibition in Human Peripheral Blood Mononuclear Cells

Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

Download

April 19, 2023

Inhibition of the E3 Ligase CBL-B Enhances the Effector Function and Proliferation of Natural Killer (NK) Cells

American Association for Cancer Research Annual Meeting 2023

Download

April 18, 2023

Phase 1/2 Study of HST-1011, an Oral CBL-B Inhibitor, Alone and in Combination with Anti-PD-1 in Patients with Advanced Solid Tumors

American Association for Cancer Research Annual Meeting 2023

Download

November 11, 2022

CBL-B Inhibition Showed Differentiated Effects in a Mixed Lymphocyte Reaction Versus Other Immuno-oncology Targeted Approaches

Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting

Download

November 11, 2022

An Allosteric, Orally Administered CBL-B Inhibitor Remodels the Tumor Microenvironment and Enhances Immune-mediated Tumor Growth Inhibition

Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting

Download

April 10, 2022

A Novel Allosteric CBL-B Inhibitor with Differentiated Immune Enhancing Activity in Preclinical Models

American Association for Cancer Research Annual Meeting 2022

Download

November 10, 2021

Identification of A Novel Allosteric Oral CBL-B Inhibitor that Augmented T Cell Response and Enhanced NK Cell Killing in vitro and in vivo

Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting

Download

Preclinical and Translational Assessment of Small Molecule IRF5 Inhibitors in Lupus-Relevant Systems

Preclinical Evaluation of IRF5 Small Molecule Inhibitors with Potent Activity in Lupus-Relevant Systems

MSS/KRASG12XCRC Depends on CBM Signalosome for Survival -A Discovery that May Transform KRASG12XCRC Therapy

Synthetic Lethality of CBM Signalosome Inhibition for KRASG12X Colorectal Cancer

Targeting IRF5: Discovery and Preclinical Development of Selective Small Molecule Inhibitors

Peripheral Blood and Tumor Gene Expression as Biomarkers and Potential Predictors of Clinical Outcome with HST-1011, an Oral CBL-B Inhibitor

Targeting the CBM Signalosome with a MALT1 Signalosome Glue for Treatment of NFκB Driven Solid Tumors

First-in-Human (FIH) Phase 1 Data of HST-1011, an Oral CBL-B Inhibitor, in Patients with Advanced Solid Tumors

Targeting the CBM Signalosome with a MALT1 Scaffolding Inhibitor for Treatment of Non-Hodgkin Lymphomas

Discovery of the First MALT1 Allosteric Scaffolding Inhibitor

Exploring Proximal Biomarkers of CBL-B Inhibition in Human Peripheral Blood Mononuclear Cells

Inhibition of the E3 Ligase CBL-B Enhances the Effector Function and Proliferation of Natural Killer (NK) Cells

Phase 1/2 Study of HST-1011, an Oral CBL-B Inhibitor, Alone and in Combination with Anti-PD-1 in Patients with Advanced Solid Tumors

CBL-B Inhibition Showed Differentiated Effects in a Mixed Lymphocyte Reaction Versus Other Immuno-oncology Targeted Approaches

An Allosteric, Orally Administered CBL-B Inhibitor Remodels the Tumor Microenvironment and Enhances Immune-mediated Tumor Growth Inhibition

A Novel Allosteric CBL-B Inhibitor with Differentiated Immune Enhancing Activity in Preclinical Models

Identification of A Novel Allosteric Oral CBL-B Inhibitor that Augmented T Cell Response and Enhanced NK Cell Killing in vitro and in vivo

Subscribe to our newsletter

Connect with us